Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3735-3742

  Sato, Norihiro ^a   Fukushima, Noriyoshi ^a   Maitra, Anirban ^a   Matsubayashi, Hiroyuki ^a   Yeo, Charles J ^a   Cameron, John L ^a   Hruban, Ralph H ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLAUDIN; DNA; HISTONE DEACETYLASE INHIBITOR; PENTRAXIN; PROTEIN CLDN5; PROTEIN NPTX2; PROTEIN SARP2; RNA; SECRETED APOPTOSIS RELATED PROTEIN 2; TRICHOSTATIN A; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHRONIC PANCREATITIS; CONTROLLED STUDY; CPG ISLAND; CYSTADENOMA; DNA METHYLATION; DNA MICROARRAY; EARLY DIAGNOSIS; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS ISLET CELL TUMOR; PANCREAS JUICE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DNA METHYLATION; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0037742210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Hruban, R. H., Iacobuzio-Donahue, C., Wilentz, R. E., Goggins, M., and Kern, S. E. Molecular pathology of pancreatic cancer. Cancer J., 7: 251-258, 2001.
3. Ueki, T., Toyota, M., Sohn, T., Yeo, C. J., Issa, J. P., Hruban, R. H., and Goggins, M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res., 60: 1835-1839, 2000.
4. Ueki, T., Toyota, M., Skinner, H., Walter, K. M., Yeo, C. J., Issa, J. P., Hruban, R. H., and Goggins, M. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res., 61: 8540-8546, 2001.
5. Fukushima, N., Sato, N., Ueki, T., Rosty, C., Walter, K. M., Wilentz, R. E., Yeo, C. J., Hruban, R. H., and Goggins, M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol., 160: 1573-1581, 2002.
6. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
7. Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2: 210-219, 2002.
8. Rosty, C., and Goggins, M. Early detection of pancreatic carcinoma. Hematol. Oncol. Clin. N. Am., 16: 37-52, 2002.
9. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., Herman, J. G., and Baylin, S. B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31:141-149, 2002.
10. Sato, N., Maehara, N., Su, G. H., and Goggins, M. Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J. Natl. Cancer Inst. (Bethesda), 95: 327-330, 2003.
11. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
12. Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jager, E., Seliger, B., and Maio, M. 5-Aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res., 8: 2690-2695, 2002.
13. Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., and Thykjaer, T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res., 62: 961-966, 2002.
14. Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., and Lowe, S. W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond.), 409: 207-211, 2001.
15. Zhu, W. G., Dai, Z., Ding, H., Srinivasan, K., Hall, J., Duan, W., Villalona-Calero, M. A., Plass, C., and Otterson, G. A. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene, 20: 7787-7796, 2001.
16. Toyota, M., Ho, C., Ohe-Toyota, M., Baylin, S. B., and Issa, J. P. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res., 59: 4535-4541, 1999.
17. Chen, B., He, L., Savell, V. H., Jenkins, J. J., and Parham, D. M. Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res., 60: 3290-3298, 2000.
18. Shin, J. Y., Kim, H. S., Park, J., Park, J. B., and Lee, J. Y. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res., 60: 262-265, 2000.
19. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampler, M. R., and Sukumar, S. High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. USA, 97: 6049-6054, 2000.
20. Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. K., Baylin, S. B., and Graft, J. R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gone suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res., 59: 798-802, 1999.
21. Chlenski, A., Ketels, K. V., Engeriser, J. L., Talamonti, M. S., Tsao, M. S., Koutnikova, H., Oyasu, R., and Scarpelli, D. G. zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. Int. J. Cancer, 83: 349-358, 1999.
22. Gardiner-Garden, M., and Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol., 196: 261-282, 1987.
23. Ueki, T., Walter, K. M., Skinner, H., Jaffee, E., Hruban, R. H., and Goggins, M. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene, 21: 2114-2117, 2002.
24. Smiraglia, D. J., Rush, L. J., Fruhwald, M. C., Dai, Z., Held, W. A., Costello, J. F., Lang, J. C., Eng, C., Li, B., Wright, F. A., Caligiuri, M. A., and Plass, C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum. Mol. Genet., 10: 1413-1419, 2001.
25. Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomaki, P., Lang, J. C., Schuller, D. E., Yu, L., Bloomfield, C. D., Caligiuri, M. A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N. J., Zhang, X., O'Dorisio, M. S., Held, W. A., Cavenee, W. K., and Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet., 24: 132-138, 2000.
26. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (Bethesda), 92: 1210-1216, 2000.
27. Li, B., Goyal, J., Dhar, S., Dimri, G., Evron, E., Sukumar, S., Wazer, D. E., and Band, V. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res., 61: 8014-8021, 2001.
28. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21: 103-107, 1999.
29. El-Osta, A., Kantharidis, P., Zalcberg, J. R., and Wolffe, A. P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDRI) on activation. Mol. Cell. Biol., 22: 1844-1857, 2002.
30. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
31. 2 phase. J. Biol. Chem., 275: 22627-22630, 2000.
32. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
33. Melkonyan, H. S., Chang, W. C., Shapiro, J. P., Mahadevappa, M., Fitzpatrick, P. A., Kiefer, M. C., Tomei, L. D., and Umansky, S. R. SARPs: a family of secreted apoptosis-related proteins. Proc. Natl. Acad. Sci. USA, 94: 13636-13641, 1997.
34. Evron, E., Dooley, W. C., Umbricht, C. B., Rosenthal, D., Sacchi, N., Gabrielson, E., Soito, A. B., Hung, D. T., Ljung, B., Davidson, N. E., and Sukumar, S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet, 357: 1335-1336, 2001.
35. Chan, M. W., Chan, L. W., Tang, N. L., Tong, J. H., Lo, K. W., Lee, T. L., Cheung, H. Y., Wong, W. S., Chan, P. S., Lai, F. M., and To, K. F. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res., 8: 464-470, 2002.
36. Tersmette, A. C., Petersen, G. M., Offerhaus, G. J., Falatko, F. C., Brune, K. A., Goggins, M., Rozenblum, E., Wilentz, R. E., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res., 7: 738-744, 2001.